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Abstract
Vaccines for protection against respiratory infections should optimally induce a mucosal immune response in the
respiratory tract in addition to a systemic immune response. However, current parenteral immunization modalities
generally fail to induce mucosal immunity, while mucosal vaccine delivery often results in poor systemic immunity. In
order to find an immunization strategy which satisfies the need for induction of both mucosal and systemic immunity,
we compared local and systemic immune responses elicited by two mucosal immunizations, given either by the
intranasal (IN) or the intrapulmonary (IPL) route, with responses elicited by a mucosal prime followed by a systemic
boost immunization. The study was conducted in BALB/c mice and the vaccine formulation was an influenza subunit
vaccine supplemented with GPI-0100, a saponin-derived adjuvant. While optimal mucosal antibody titers were
obtained after two intrapulmonary vaccinations, optimal systemic antibody responses were achieved by intranasal
prime followed by intramuscular boost. The latter strategy also resulted in the best T cell response, yet, it was
ineffective in inducing nose or lung IgA. Successful induction of secretory IgA, IgG and T cell responses was only
achieved with prime-boost strategies involving intrapulmonary immunization and was optimal when both
immunizations were given via the intrapulmonary route. Our results underline that immunization via the lungs is
particularly effective for priming as well as boosting of local and systemic immune responses.
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Introduction
The aim of mucosal immunization against respiratory virus
infections is the induction of local immunity at the port of
pathogen entry. In particular, mucosal antibodies can readily
neutralize invading viruses at the luminal site of the epithelial
layer and prevent their entry into host cells. Such an immune
exclusion effect is mainly mediated by secretory IgA (SIgA),
which is effectively induced by mucosal but not parenteral
immunization [1–5]. Moreover, intracellular viruses can be
neutralized during transcytosis of dimeric SIgA through the
epithelial layer. Furthermore, for rapidly changing viruses like
influenza virus, SIgA has been shown to be more cross-
reactive than IgG and to neutralize antigen-drifted
homosubtypic and even antigen-shifted heterosubtypic virus
strains [6].
Despite the advantage of mucosal immunization for the
induction of SIgA responses, the mucosal route is suboptimal
for the induction of systemic antibody responses [7–9]. In case
of influenza, systemic antibodies are important since they
contribute to protection against virus replication in the lungs
and are the only correlate of protection so far recognized by
regulatory authorities [10]. Furthermore, due to the default Th2-
oriented nature of mucosal immunity, mucosal immunization
shows limited induction of Th1-related antibody subtypes (eg.
IgG2a in Balb/c mice), which are preferable for viral clearance
[11–15].
A potential way to combine the advantages of mucosal and
systemic immunization involves prime-boost strategies with
mucosal priming and systemic boosting or vice-versa. Several
studies have investigated such strategies, but the majority of
these make use of DNA vaccines and/or recombinant virus
vaccines during priming, boosting or both [16–26]. So far, little
is known about prime-boost strategies for optimization of
mucosal and systemic immune responses to protein-based
influenza vaccines. A study in horses using an ISCOM-
adjuvanted influenza vaccine showed that intranasal boosting
after intramuscular (IM) priming does not have much effect on
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serum IgG levels, but results in low and transient SIgA and IgG
responses in nose washes [18]. However, no comparison was
performed with alternative immunization strategies.
We earlier showed that GPI-0100, a semi-synthetic saponin-
derivative, is a very effective adjuvant for influenza subunit
vaccine administered via not only the intramuscular, but also
the intranasal and particularly the intrapulmonary route [27,28].
Here, we used GPI-0100-adjuvanted influenza vaccine to
identify an immunization strategy that effectively elicits
influenza-specific immune responses at both mucosal and
systemic sites. To this end, we compared the immune
responses elicited by two mucosal strategies with the
adjuvanted influenza vaccine to the responses obtained by a
strategy involving a mucosal prime followed by a systemic
booster immunization. Two different mucosal administration
routes were evaluated: intranasal (IN) and intrapulmonary
(IPL). We observed that systemic boosting was not as effective
as mucosal boosting for induction of mucosal SIgA. Systemic
boosting enhanced systemic IgG titers to higher levels than
mucosal boosting in IN-primed, but not in IPL-primed mice. Yet,
systemic boosting generally stimulated stronger Th1 cellular
immunity than mucosal boosting. All the immunization
strategies we tested in the current study provided complete
protection against influenza virus infection.
Materials and Methods
GPI-0100
GPI-0100 was purchased from Hawaii Biotech, Inc. (Aiea, HI,
USA) and was stored at 4 °C. A 10 mg/ml stock solution was
prepared in HBS buffer (5 mM Hepes, 150 mM NaCl and
0.1 mM EDTA, pH 7.4) as described previously [27].
Subunit vaccine and challenge virus preparation
A stock of A/Puerto Rico/8/34 (H1N1) influenza virus (PR8)
propagated on Madin-Darby canine kidney (MDCK) cells was
kindly provided by Solvay Biologicals (Weesp, Netherlands)
and further propagated on embryonated eggs. Virus titer was
determined by measuring the tissue culture infectious dose 50
(TCID50) [27].
For subunit vaccine preparation, the procedure was as
previously described [27]. Briefly, PR8 virus was inactivated by
β-propiolactone (0.1% in citrate buffer, freshly prepared). The
inactivated virus sample was dialyzed against HBS buffer
(5 mM Hepes, 150 mM NaCl and 0.1 mM EDTA, pH 7.4) and
then solubilized by Tween 80 (0.6 mg/ml) and
hexadecyltrimethylammonium bromide (CTAB, 3.0 mg/ml). The
viral nucleocapsid was further removed from the preparation by
ultracentrifugation. Subsequently, detergents were removed by
Biobeads SM2 (634 mg/ml, Bio-Rad, Hercules, Canada) pre-
washed with methanol.
Protein content of the subunit material was determined by a
modified Lowry assay [29]. Hemagglutinin (HA) content was
assumed to be equal to the total protein for subunit material
based on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) results which indicate presence
of only minor amounts of other viral proteins [30]. Vaccines
were mixed at the indicated amounts of subunit and GPI-0100
just before immunization.
Animal handling
The protocol for the animal experiments described here was
approved by the Ethics Committee on Animal Research of the
University of Groningen.
For immunization experiments, female Balb/c mice (Harlan,
Horst, Netherlands) aged 8–10 weeks were grouped (n = 6 per
group) and immunized IM, IN or IPL with 1 µg PR8 subunit
vaccine with or without 15 µg GPI-0100 in a two-dose
immunization regimen with a 20 day interval (Table 1). For IM
immunizations, vaccines in 50 µl were divided over both hind
legs. For IN immunizations, vaccines in 5 µl were slowly
delivered with a pipet and divided over both nares thus
confining the antigen to the nose [31]. For IPL immunizations,
mice were brought to an upright position after isoflurane
anesthesia and the trachea was intubated with a modified
Autoguard catheter (Becton Dickinson BV, Breda,
Netherlands). Vaccines in 50 µl were then delivered with the
help of an IA-1C Microsprayer Aerosolizer attached to a
FMJ-250 High Pressure Syringe (both from Penn-Century Inc.,
Wyndmoor, PA, USA).
Pre-boost blood samples were collected on day 20 by orbital
puncture prior to the second immunization. For immunization
experiments, mice were sacrificed on day 27 and nose wash,
lung wash, blood and spleen samples were collected for ex
vivo immuno-assays. Mucosal wash samples were collected in
1 ml phosphate-buffered saline (PBS) containing protease
inhibitor (Complete Protease Inhibitor Cocktail, Roche, IN,
USA).
For challenge experiments, mice received the immunization
regimen as described above. Pre-boost and pre-challenge
serum samples were collected on day 20 and day 34 by orbital
puncture prior to immunization or virus infection, respectively.
On day 34, mice were infected intranasally with 200 TCID50
PR8 influenza virus in 50 µl of HBS buffer. The virus infection
was carried out under isoflurane anesthesia to ensure
deposition of the virus into the lungs. Mice were monitored
twice a day at fixed time points for clinical signs of illness
including weight loss and changes in behavior or appearance.
Mice were bled and sacrificed on day 37. Nasal wash, serum
and spleen samples were collected for immuno-assays. The
lung lobes were collected in 1 ml PBS for homogenization and
the processed samples were stored at -80°C for later
determination of lung virus titers.
Table 1. Immunization scheme.
Treatment Groups Vaccine formulation Administration route
  Day 0 Day 20
2M 1 µg PR8 subunit IM IM
2N 1 µg PR8 subunit + 15 µg GPI-0100 IN IN
N+M 1 µg PR8 subunit + 15 µg GPI-0100 IN IM
2P 1 µg PR8 subunit + 15 µg GPI-0100 IPL IPL
P+M 1 µg PR8 subunit + 15 µg GPI-0100 IPL IM
Immunization Scheme and Flu Vaccine Immunogenicity
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IgA, IgG, IgG1 and IgG2a ELISA
H1N1-specific antibody responses were determined by
ELISA as previously described [28]. For nasal SIgA and IgG
responses, OD 492 of individual samples is given. For lung
SIgA and IgG responses, the average OD 492 (with the
standard error of the means (S.E.M.)) for each group at each
dilution was calculated. For serum IgG response, the titer for
individual samples was calculated as the10 log of the reciprocal
of the sample dilution corresponding to an OD 492 of 0.2. For
calculation purposes, sera with titers below the detection limit
were assigned an arbitrary titer corresponding to half of the
detection limit.
Calibration plates for IgG1 and IgG2a assay were coated
with 0.1 µg goat anti-mouse IgG (SouthernBiotech). Increasing
concentrations of purified mouse IgG1 or IgG2a
(SouthernBiotech) were added to the plates. IgG1 and IgG2a
responses detected from individual sample are given as
concentration (μg/ml) of H1N1-specific IgG1 and IgG2a.
Hemagluttination inhibition (HAI)
Serum samples were processed and HAI titers were
determined as described previously [28]. 2log HAI titers for
individual mice are presented.
ELISPOT
H1N1-specific IFN-γ and IL-4 responses were determined by
ELISPOT assays as previously described [27]. Numbers of
influenza-specific IFN-γ- or IL-4-secreting cells per 5x105
splenocytes for each mouse are given.
Virus titration
Lungs collected from the immunized and challenged mice
were homogenized in PBS and stored at −80°C until use. Virus
titers were determined by inoculating serial dilutions of the
clarified homogenates on MDCK cells, as described earlier
[28]. The titers of individual mice are given and the results are
presented as10 log virus titer per gram of lung tissue.
Statistics
The unpaired Student’s t-test was used to determine if the
differences in influenza-specific responses observed between
groups of mice were significant. A p value of p < 0.05 was
considered significant. Spearman (nonparametric) correlation
analysis was performed to assess the relationship observed
between serum and mucosal influenza-specific IgG responses.
Results
Effect of immunization strategy on mucosal antibody
titers
Since induction of a mucosal SIgA response is the central
aim of mucosal immunization, we first evaluated the effect of
the immunization strategy on the induced SIgA response. Mice
received GPI-0100-adjuvanted influenza vaccine via the IN or
IPL route on day 0 and received a second immunization on day
20 via the same mucosal route or IM. A control group
immunized twice IM with non-adjuvanted vaccine served as a
reference. Six mice of each group were sacrificed one week
after the booster immunization for the collection of lung wash
samples. The other six mice of each group were challenged
with PR8 virus two weeks after the booster and sacrificed three
days later for collection of nose wash samples.
H1N1-specific SIgA ELISA performed on the lung wash
samples showed that mice primed with the adjuvanted vaccine
via the IN route did not develop detectable lung SIgA titers after
mucosal or systemic booster (Figure 1A). In contrast, lung SIgA
was readily detectable in mice primed via the IPL route and
boosted either via the same route or via the IM route. Yet, the
IPL/IPL approach (2P) resulted in significantly higher lung SIgA
titers than the IPL/IM approach (P+M; p=0.0109). As expected
the IM/IM immunized reference group did not develop
detectable lung SIgA titers.
H1N1-specific SIgA ELISA on nose wash samples revealed
that IN-primed mice did not develop detectable nasal SIgA
responses even after a booster via the mucosal or systemic
route and challenge with live virus (Figure 1B). In contrast, IPL-
primed mice developed robust nasal SIgA responses, but only
when the booster was given also via the IPL route (p=0.0057
for the comparison between 2P and P+M). Marginal SIgA
amounts were found in nose washes from IM/IM-immunized
animals.
As mucosal IgG has been suggested to play a role in lung
protection against influenza virus infection, we further
evaluated the effect of the different immunization strategies on
lung and nose IgG responses [9]. Mice primed with the IN
vaccine and boosted IM developed significantly higher levels of
lung IgG (Figure 1C) and nose IgG (Figure 1D) than mice
primed and boosted via the IN route (p=0.0474 and 0.02 for the
comparison between the 2N and N+M groups in Figure 1C and
1D, respectively). Interestingly, mice primed with the IPL
vaccine and boosted IM developed significantly lower lung IgG
titers than those immunized IPL during prime and boost
(p<0.0001 for the comparison between the 2P and P+M group
in Figure 1C). With respect to IN IgG titers, there was no
difference between these immunization groups. For the IM/IM
control group, low levels of IgG were detected in lung washes
but not in nose washes.
Taken together, these results indicate that while IPL
immunization optimally primed and boosted mucosal antibody
responses, IN route was ineffective in priming and boosting
mucosal responses against GPI-0100-adjuvanted subunit
vaccine.
Effect of immunization strategy on systemic antibody
responses
We next evaluated the effect of immunization strategy on
systemic antibody responses elicited by GPI-0100-adjuvanted
influenza vaccine. Both IN, and IPL priming resulted in
detectable IgG responses by day 21 (Figure S1). Yet, the titers
were significantly lower for IN-primed mice (p=0.0005). Sera of
the immunized mice were again collected two weeks after the
booster prior to virus challenge. H1N1-specific IgG ELISAs
performed on the serum samples showed that mice that
received the adjuvanted influenza vaccine by IN/IN
immunization (2N) developed an average IgG titer of 4.42,
Immunization Scheme and Flu Vaccine Immunogenicity
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Figure 1.  H1N1-specific mucosal SIgA and IgG responses
elicited by different immunization strategies.  Mice (n=12
per group) were immunized twice with a 20 day interval
according to Table 1 and either sacrificed one week later (A, C)
or challenged on day 34 and sacrificed 3 days later (B, D). (A)
Evaluation of lung SIgA responses after two immunizations.
Average OD 492 at each dilution ± standard error of the mean
(S.E.M.), n = 6. The starting and ending dilutions are 2 and
4096 respectively. (B) Nasal SIgA responses after two
immunizations and live virus challenge. OD 492 readings at 2-
fold dilution are given for individual mice. The black line
presents the geometric mean per group. (C) Lung IgG
responses after two immunizations. Average OD 492 at each
dilution ± standard error of the mean (S.E.M.), n = 6 for 2M, 2N
and N+M, and n=5 for the other groups. The starting and
ending dilutions are 2 and 4096 respectively. (D) Nasal IgG
responses after two immunizations and virus challenge.
Individual OD 492 at 2-fold dilution with geometric mean per
group is given. Groups are named as outlined in Table 1.
Levels of significance are depicted as follows: *p < 0.05, **p <
0.01 and ***p < 0.005.
doi: 10.1371/journal.pone.0069649.g001
similar to 4.98 from the IM/IM-immunized control group (Figure
2A). The IgG responses in mice immunized by the IN/IM
approach (N+M) were significantly enhanced to an average
titer of 6.16 (p<0.0001 for the comparison between the 2N and
N+M group). On the other hand, for IPL-primed mice the
booster route had no significant effect on serum IgG responses
which were 6.03 and 5.75 for IPL/IPL and IPL/IM-immunized
mice, respectively.
Sera of the immunized and challenged mice were collected
three days after the challenge upon sacrifice for the evaluation
of hemagglutination-inhibition (HAI) titers. Mice immunized with
plain influenza vaccine by IM/IM immunization developed an
average2 logHAI titer of 7.5 (Figure 2B). None of the mice
receiving GPI-0100-adjuvanted influenza vaccine by IN/IN
immunization developed detectable HAI titers. However, 5 out
of the 6 mice receiving the adjuvanted vaccine by the IN/IM
approach developed detectable serum HAI titers with an
average titer of 7.83, similar to the IM/IM control group. Mice
receiving the adjuvanted vaccine IPL/IPL or IPL/IM developed
comparable serum HAI titers. With an average titer of 5.6 and
4.8 these were somewhat lower than those obtained by the
control group and the IM/IN regimen. Yet, these differences did
not reach statistical significance.
Taken together, an immunization strategy involving a
mucosal prime followed by a systemic boost improved the
systemic antibody responses elicited by IN, but not by IPL
vaccine administration.
Effect of immunization strategy on the phenotype of the
immune response
We next examined the phenotype of the antibody responses
by performing H1N1-specific IgG1 and IgG2a ELISA assays on
the post-challenge serum samples mentioned above. Mice
receiving plain influenza vaccine by IM/IM immunization
developed serum IgG1 with an average of 113 µg/ml (Figure
3A). Those receiving GPI-0100-adjuvanted influenza vaccine
by IN/IN vaccination, however, barely developed detectable
serum IgG1 responses. IN/IM delivery of the adjuvanted
vaccine resulted in significantly enhanced IgG1 responses with
an average of 215 µg/ml (p=0.0071). Robust serum IgG1
responses were observed in mice receiving the adjuvanted
vaccine by both IPL/IPL and IPL/IM immunization, with an
average serum IgG1 of 371 and 301 µg/ml, respectively.
IgG2a responses were low in all mice immunized twice IM,
IN, or IPL, except for one mouse in the IPL group (Figure 3B).
Interestingly, systemic boost resulted in significantly enhanced
serum IgG2a responses in 5 out of the 6 IN-primed mice
(p=0.0057 for the comparison between 2N and N+M). In
contrast, systemic boost had a negative effect if any on IgG2a
titers in IPL-primed mice. Irrespective of the immunization
strategy, the overall antibody responses elicited by GPI-0100-
adjuvanted subunit influenza vaccine were dominated by the
Th2-related antibody subtype IgG1.
To evaluate the effect of immunization strategy on cellular
immune responses elicited by GPI-0100-adjuvanted influenza
vaccine, spleens of the immunized mice were collected one
week after the booster upon termination. H1N1-specific IFN-γ
responses were barely detectable in mice receiving plain
Immunization Scheme and Flu Vaccine Immunogenicity
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Figure 2.  H1N1-specific systemic IgG and hemagluttination inhibition (HAI) titers elicited by different immunization
strategies.  Serum samples from the mice described in the legend to Figure 1 were collected on day 34 prior to virus challenge (A)
and day 37 upon sacrifice (B). (A) Total IgG responses after two immunizations. 10log IgG titers of individual mice and the
geometric mean per group are given. (B) HAI titers after two immunizations and virus challenge. Individual 2log HAI titers and the
geometric mean per group are given. Due to technical reasons only 5 samples from the 2P treatment group were available for the
HAI assay.
doi: 10.1371/journal.pone.0069649.g002
Immunization Scheme and Flu Vaccine Immunogenicity
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Figure 3.  Phenotype of the H1N1-specific systemic antibody responses.  Post-challenge serum samples from the mice
described in the legend to Figure 1 were analyzed. Individual H1N1-specific IgG1 (A) and IgG2a (B) responses (μg/ml) and the
arithmetic means per group are given.
doi: 10.1371/journal.pone.0069649.g003
Immunization Scheme and Flu Vaccine Immunogenicity
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influenza vaccine IM or those receiving GPI-0100-adjuvanted
influenza vaccine IN or IPL (Figure 4A). Interestingly, influenza-
specific IFN-γ responses in mucosally-primed mice were
significantly enhanced by IM boost as compared to mucosal
boost (p=0.0264 and 0.004 for the comparison of 2N and N+M
and the comparison of 2P and P+M respectively). H1N1-
specific IL-4 responses were readily detected in all immunized
mice but were relatively lower in mice immunized via the IN/IN
regimen. In IN-primed mice, IM boost was significantly more
effective then IN boost in enhancing the number of IL-4-
producing T cells (p=0.004 for the comparison of 2N and N+M).
A similar effect was not observed in IPL-primed mice.
Effect of immunization strategy on lung protection
against influenza virus infection
To evaluate the effect of the immunization strategy on
protection against virus challenge, the immunized mice were
infected with live virus 14 days after the booster immunization
and lung virus titers were determined three days later, at the
peak of viral replication. Mock-immunized control mice
developed an average lung virus titer of 3.5910 log/g lung tissue
(Figure 5). The lung virus titer was under the detection limit in 5
out of the 6 mice of the IM-immunized control group; one
mouse of this group developed a titer of 2.5910 log/g lung
tissue. Lung virus titers were not detectable in any of the mice
that received GPI-0100-adjuvanted influenza vaccine either
twice via one of the mucosal routes or by a mucosal prime
followed by a systemic boost. Thus, the adjuvanted vaccine
provided complete protection of the lungs from virus growth
irrespective of the immunization strategy followed.
Discussion
In the present study, we evaluated the effect of the
immunization strategy on the immunogenicity and protective
capacity of a GPI-0100-adjuvanted PR8 influenza subunit
vaccine. Interestingly, we observed that the optimal boosting
route for IN- and IPL-primed mice was different. IN-primed
mice developed no mucosal and poor systemic antibody
responses when boosted via the IN route. Boosting of IN-
primed mice via the IM route, however, resulted in detectable
mucosal IgG (though not SIgA) responses, strong systemic
antibody responses, enhanced T cell responses and the
induction of IgG2a, an antibody subtype associated with
improved virus clearance [13]. For IPL-primed mice, IPL/IPL
immunization was very effective in inducing mucosal SIgA and
IgG as well as systemic antibodies. IPL/IM approach, on the
other hand, resulted in relatively modest mucosal antibody
responses, although it was equally effective as IPL/IPL strategy
for the induction of systemic antibody responses. Despite the
different immune profiles, challenge experiments showed that
GPI-0100-adjuvanted influenza vaccine delivered by all
regimes provided complete protection of the lungs from
homologous virus infection.
Our results reveal that mucosal immune responses to prime-
boost immunization are affected by both the priming as well as
the boosting route. For IN priming, we used a low vaccine
volume of 5 µl to retain the antigen in the nasal cavity [31]. This
allowed us to clearly distinguish IN from IPL immunization. We
observed that IPL but not IN immunization was effective in
inducing mucosal SIgA as well as IgG responses. While the
robust mucosal antibody titers observed from the IPL/IPL group
could be a result of successful induction of local memory
responses, the poor mucosal responses in the IN/IN group
indicate that IN delivery of influenza vaccine used in the current
study barely primed mucosal responses. Yet, IM boost of IN-
primed mice though not inducing mucosal SIgA responses did
elicit mucosal IgG responses. It has been reported that
mucosal IgG can be derived from serum when present in high
concentration, and reaches the nose and especially the lungs
by transudation [32]. Indeed, except for the IPL/IPL group,
mucosal and serum IgG responses elicited from the other
groups shared the same trend: IN/IN < IM/IM << IN/IM = IP/IM.
The positive correlation between mucosal and serum IgG
responses from these groups were confirmed by Spearman
analysis (The coefficient for nose IgG vs. serum IgG and lung
IgG vs. serum IgG are 0.59 (p=0.0013) and 0.72 (p<0.0001)
respectively). Our results are generally in line with an earlier
study by Minne and coworkers who tested to which extent the
delivery site in the respiratory tract impacts on the immune
response elicited by influenza vaccines [33]. These authors
used mice primed IN with a whole inactivated virus vaccine
administered in a volume of 20 µl. The primed mice were then
boosted by administration of split antigen to different parts of
the respiratory tract or to the hind muscles. An IN boost
resulted in poor mucosal antibody responses (except for nose
SIgA) while administration deep into the lungs elicited strong
nose and lung SIgA and IgG responses as observed in our
study. An IM boost was not effective in stimulating mucosal
SIgA, but did boost mucosal IgG responses to similar extents
as a boost deep into the lungs. Thus, in agreement with our
previous study, we conclude that the IPL route is much more
effective than the IN route for priming mucosal antibody
responses [28]. Moreover, it is the optimal route for boosting
such responses.
Next to mucosal antibodies, systemic IgG antibodies play an
important role in protection from severe influenza illness, since
they can transudate into the lungs and prevent excessive viral
replication and tissue damage upon infection [32]. This is the
basis for protection provided by conventional parenterally
administered influenza vaccines. In our study, priming via
either the IN or the IPL route resulted in detectable serum IgG
responses 21 days later, although these responses were
significantly lower for IN-primed mice (Figure S1). An IN boost
did stimulate the serum IgG responses, but HAI titers could not
be detected. An IM boost was essential to achieve systemic
antibody responses comparable to or even better than those of
the control group immunized IM with non-adjuvanted vaccine.
Therefore, even though IN priming elicited only very modest
serum antibody responses, memory B cells formed through the
priming could be readily activated upon IN or IM boosting. Yet,
optimal boosting required antigen administration via the IM
route. Our results confirm earlier results from studies on
influenza, HSV, HIV-1, and SARS, which all found that IN
priming, whether given by protein, DNA or recombinant virus
vaccines, should be followed by IM boost for induction of
Immunization Scheme and Flu Vaccine Immunogenicity
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Figure 4.  H1N1-specific cellular immunity elicited by different immunization strategies.  Post-challenge spleen samples from
the mice described in the legend to Figure 1 were collected upon termination. Splenocytes were isolated and stimulated overnight
with PR8 subunit. (A) Numbers of H1N1-specific IFN-γ producing cells per 5x105 splenocytes of individual mice are given. (B)
Numbers of H1N1-specific IL-4 producing cells per 5x105 splenocytes of individual mice are given. The black line represents the
arithmetic mean per group.
doi: 10.1371/journal.pone.0069649.g004
Immunization Scheme and Flu Vaccine Immunogenicity
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optimal serum antibody responses [21,23,24,33]. For IPL-
primed mice, IM and IPL boosting were equally effective in
eliciting serum IgG and HAI titers. Also in our earlier study and
in the study by Minne et al., an IPL boost was found to result in
particularly strong systemic antibody responses [28,33]. Thus,
strong systemic antibody responses can be achieved by either
two IPL immunizations or IPL priming followed by IM boosting.
In addition to the magnitude, the phenotype of an immune
response also determines the effectiveness of its protection
against invading pathogens. A Th1 type immune response,
characterized by IgG2a and IFN-γ production in mice, has been
shown to correlate positively with improved protection against
influenza virus [13,30]. Yet, Th1 immunity was barely induced
by IM/IM immunization with plain influenza vaccine or IN/IN
immunization with GPI-0100-adjuvanted influenza vaccine. IM
boosting of IN-primed mice significantly enhanced the Th1 arm
of the immune response. The superior quality of the immune
responses elicited by IN/IM immunization over IN/IN
immunization, and even IM/IM immunization with unadjuvanted
vaccine, was in line with earlier studies [21,23,24,33]. As for
IPL immunization, GPI-0100-adjuvanted influenza vaccine
elicited marginal IgG2a and IFN-γ responses using IPL/IPL
approach. Interestingly, IM boosting somewhat decreased the
IgG2a response, but significantly enhanced the IFN-γ response
of IPL-primed mice. This is in contrast to the study by Minne et
al., which showed that IM and IPL boost are both effective in
eliciting IgG2a and IFN-γ responses [33]. The different results
from the two studies are possibly due to differences in the
vaccine formulations used. Minne et al. used a high dose (5 µg
HA) of whole inactivated virus (WIV) and a low dose (1.5 µg
HA) of split virus for the priming and boosting respectively. WIV
possesses natural adjuvant activity from ssRNA (as TLR-7
ligand) and effectively induces Th1 responses [34]. Subunit
vaccine used in the current study, on the other hand, is rather
ineffective in eliciting Th1 responses and results in a Th2-
dominated immune phenotype. Although IM boosting enhances
Th1 immunity of IN and IPL vaccines to a different extent, the
overall immune responses elicited by GPI-0100-adjuvanted
influenza vaccine administered following different immunization
strategies were dominated by a Th2 phenotype.
Figure 5.  Effect of different immunization strategies on lung virus titers upon challenge.  Lung samples from the challenged
mice described in the legend to Figure 1 were collected upon termination. Virus titers measured in the lung homogenates are
expressed as the 10log virus titer per gram of lung tissue. Individual lung virus titers with the geometric mean titer per group are
depicted.
doi: 10.1371/journal.pone.0069649.g005
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Taken together, immunization strategies involving a mucosal
prime followed by a systemic booster or IPL/IPL with properly
adjuvanted influenza vaccines are at least as effective as
conventional parenteral immunization in inducing systemic
antibody responses. This is important since regulatory
authorities request that influenza vaccines fulfill quality criteria
based on serum HAI titers [35]. Meanwhile, pulmonary
immunization probably also raises local memory B cell and T
cell responses in the respiratory tract, a phenomenon observed
upon influenza infection but not upon intramuscular
immunization [36,37]. Thus, mucosal priming is essential for
the localization of memory immunocytes to the respiratory tract,
which would allow them to respond rapidly to an influenza virus
challenge [36,38–40]. Moreover, memory B cells primed by the
mucosal, but not the systemic, route preferentially express
SIgA, which is the major antibody subtype which mediates
early immune exclusion and also exhibits cross-protective
capacity. Hence, IN/IM, IPL/IM or IPL/IPL immunization
regimens should be further explored to come to optimized
immunization regimens for protection from respiratory viral
infections.
Supporting Information
Figure S1.  H1N1-specific systemic IgG primed by different
immunization routes.  Serum samples from the mice
described in the legend to Figure 1 were collected on day 20
prior to the second immunization. Total IgG responses from
2M, N+M and P+M groups after priming are given.
(TIF)
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